Biocryst Pharmaceuticals Inc financial data

Symbol
BCRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
4505 Emperor Boulevard, Suite 200, Durham, North Carolina
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 431 % -21.2%
Quick Ratio 25.4 % -11.5%
Return On Equity 48.2 % -42.6%
Return On Assets -41 % +3.69%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 206 M shares +9.23%
Common Stock, Shares, Outstanding 206 M shares +9.25%
Entity Public Float 1.32 B USD
Common Stock, Value, Issued 2.06 M USD +9.21%
Weighted Average Number of Shares Outstanding, Basic 206 M shares +9.31%
Weighted Average Number of Shares Outstanding, Diluted 206 M shares +9.31%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 215 M USD -9.16%
Costs and Expenses 445 M USD +6.87%
Operating Income (Loss) -89.8 M USD +29.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -209 M USD +6.52%
Income Tax Expense (Benefit) 4 K USD -99.9%
Net Income (Loss) Attributable to Parent -209 M USD +7.81%
Earnings Per Share, Basic -1.07 USD/shares +11.6%
Earnings Per Share, Diluted -1.07 USD/shares +11.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.3 M USD -45.6%
Accounts Receivable, after Allowance for Credit Loss, Current 60.6 M USD +24.6%
Inventory, Net 29.8 M USD +8.43%
Assets, Current 447 M USD -8.92%
Property, Plant and Equipment, Net 7.83 M USD -6.51%
Operating Lease, Right-of-Use Asset 8.86 M USD +25.8%
Other Assets, Noncurrent 13 M USD +83.9%
Assets 468 M USD -8.21%
Accounts Payable, Current 11.9 M USD +90.4%
Employee-related Liabilities, Current 36.5 M USD +65.1%
Accrued Liabilities, Current 79.2 M USD +5.37%
Liabilities, Current 120 M USD +40.8%
Operating Lease, Liability, Noncurrent 8.6 M USD +44.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 771 K USD +31.8%
Retained Earnings (Accumulated Deficit) -1.72 B USD -13.8%
Stockholders' Equity Attributable to Parent -476 M USD -45%
Liabilities and Equity 468 M USD -8.21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -53.7 M USD -13%
Net Cash Provided by (Used in) Financing Activities -1.05 M USD -121%
Net Cash Provided by (Used in) Investing Activities 28.8 M USD
Common Stock, Shares Authorized 450 M shares 0%
Common Stock, Shares, Issued 206 M shares +9.25%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -26.3 M USD +82.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.99 M USD -30.2%
Deferred Tax Assets, Valuation Allowance 437 M USD +12.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 441 M USD +12.6%
Operating Lease, Liability 9.69 M USD +15.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -208 M USD +7.73%
Lessee, Operating Lease, Liability, to be Paid 16.1 M USD +18.2%
Property, Plant and Equipment, Gross 19.1 M USD +5.25%
Operating Lease, Liability, Current 1.1 M USD -55.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.66 M USD -2.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.85 M USD -14.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) -682 K USD -6300%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.4 M USD +23.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.58 M USD +92.2%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 992 K USD -63.6%
Preferred Stock, Shares Authorized 5 M shares +99900%
Unrecognized Tax Benefits 14.4 M USD +3.74%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.42 M USD +131%
Operating Lease, Payments 2.02 M USD +44%
Additional Paid in Capital 1.24 B USD +5.13%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 306 K USD -24.4%
Share-based Payment Arrangement, Expense 13.7 M USD -2.53%
Interest Expense 105 M USD +2.63%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%